Rain oncology stock.

Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing.About Rain Oncology Inc. Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.We would like to show you a description here but the site won’t allow us.Assuming positive data from the MANTRA trial, the competition might need to improve upon the benchmark set by Rain Oncology, writes the analyst. Rain had $109.8 million in cash, cash equivalents ...

Rain Oncology Inc 52 week high is $14.48 as of November 24, 2023. What is the 52-week low for Rain Oncology Inc? 52 week low is the lowest price of a stock in the past 52 weeks, or one year.Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ...Stock analysis for Rain Oncology Inc (RAIN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Web

Save your passwords securely with your Google Account. Stay signed out Sign in Sign inNovartis, Pfizer, EMD-Serono , Sanofi Oncology, Janssen Oncology, Ignyta (now Roche), Roche/ ... Shareholder / Stockholder / Stock options: Rain Therapeutics; ...

Success is Achieved Together. Biosimulation can reduce the size of and cost of human trials, the most expensive and time-consuming part of drug development. In some cases, we can eliminate certain human trials completely. More than 2,000 customers worldwide choose us as their partner for biosimulation software and technology-driven services.Oct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net ...Stocks / Pharmaceuticals & Biotech RAIN Rain Oncology NasdaqGS:RAIN Stock Report Add to watchlist Add to portfolio Last Price US$1.07 Market Cap …4 Aug 2023 ... NEW YORK, Aug. 4, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the ...

May 11, 2023 · NEWARK, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reports financial results for the first quarter ...

RAIN Stock 12 Months Forecast. $1.33. (20.91% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Rain Therapeutics in the last 3 months. The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 20.91% change from the last price of $1.10.Web

Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.Stock Detail•Compare Perf. •Options Chain•Save to Portfolio•Create Alert Scroll to Statements Show Previous Ratings Rain Oncology, Inc. is a clinical-stage precision …Rain Oncology's stock has fallen near 25% following postponement of milademetan's top-line results and increased net losses reported in Q4 2022 and full year 2022. Click here to read more.WebPredictive Oncology Inc. (NASDAQ:POAI) posted its earnings results on Wednesday, August, 11th. The medical instruments supplier reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.60) by $0.60. The medical instruments supplier earned $0.35 million during the quarter, compared to …Which Rain Oncology insiders have been buying company stock? The following insiders have purchased RAIN shares in the last 24 months: Aaron I Davis ($5,667,995.96), Bvf Partners L P/Il ($9,971,387.14), Franklin M Berger ($351,000.00), and Kevin C Tang ($1,179,304.12).WebDescription. Rain Oncology Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic approach to select patients based on their tumors' underlying genetics rather than histology.

Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.The offer is just the latest example of Concentra hoping to snap up a troubled biotech this year, after a reach out to Rain Oncology last month. Tang has already scored success when Concentra used ...Track Rain Therapeutics Inc (RAIN) Stock Price, Quote, latest community messages, chart, news and other stock related information.Find the latest ALX Oncology Holdings Inc. (ALXO) stock quote, history, news and other vital information to help you with your stock trading and investing.Nov 4, 2022 · Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The shares are being sold at an offering price of $5.83 per ...

Nov 4, 2022 · NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...

As of November 3, 2023, Rain had approximately 36.4 million shares of common stock outstanding. About Rain Oncology Inc. Rain Oncology Inc. is a precision oncology company developing therapies ...WebOct 16, 2023 · Oct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net ... Get the latest Rain Oncology Inc (RAIN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Of course Rain Oncology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate ...WebBragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Rain Oncology, Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or …

Stock Quote & Chart. Historical Price Lookup. ... Rain Oncology Announces Collaborator Poster Presentation at the American Association for Cancer Research (AACR ...

Rain Oncology last announced its earnings data on November 9th, 2023. The reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. Rain Oncology has generated ($2.06) earnings per share over the last year (($2.06) diluted earnings per share).

1 Mar 2023 ... ... stock market cnbc awaaz,union budget 2023 ... Rain Industries Stock Analysis | Rain Industries Latest News Today | Share Analysis Business Model.4 Wall Street analysts have issued 1 year target prices for Pyxis Oncology's stock. Their PYXS share price targets range from $7.00 to $14.00. On average, they anticipate the company's share price to reach $10.50 in the next twelve months. This suggests a possible upside of 629.2% from the stock's current price.Rain Oncology stock plummets on late-stage cancer drug results - San Francisco Business Times bizjournals.com 1 Like Comment Share Copy; LinkedIn; Facebook; Twitter; To view ...NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The …WebThe number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Rain Oncology Inc have a median target of 1.38, with a high estimate of 2.00 and a low estimate of 1.00. The median ...Top Pharmaceuticals & Drugs Stocks in India by Market Capitalisation: Get the List of Top Pharmaceuticals & Drugs Companies in India (BSE) based on Market CapitalisationRain Oncology is a clinical-stage company researching, developing and translating innovative targeted therapies for patients with cancer to help provide them hope to get their lives back. Our ...WebGet Rain Oncology Inc (RAIN.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsWebRain Oncology Inc. Watch list NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:58 p.m. EST Delayed quote $ 1.1100 0.00 0.00% After Hours Volume: 1.31K Advanced Charting... Rain Oncology is latest troubled biotech to receive acquisition offer from Concentra. By James Waldron Oct 16, 2023 10:20am. mergers and acquisitions Tang Capital Partners Deals. Five months after ...

Rain Oncology is a late-stage oncology company specializing in precision oncology by targeting oncogenic drivers. Click here to see why the stock is a speculative buy.We see a spike in Rain Oncology’s stock price after the offer though it is still $0.20 below the $1.25 offer price which does leave out some premium for M&A arbitrageurs. The intriguing aspect of this development is the involvement of Tang Capital Partners, which had previously disclosed a substantial 14.1% stake in Rain Oncology.WebOncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass" and the word λόγος (logos), meaning "study".Cancer survival has ...Instagram:https://instagram. benzinga optionsputs va callspins pricevanguard vis 12 brokers have issued 12-month price objectives for Rain Oncology's stock. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate …NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of ...Web cheapest stocks to buy nowibond rate today Jun 15, 2023 · Rain Oncology has a market capitalisation of US$46m and burnt through US$68m last year, which is 147% of the company's market value. That suggests the company may have some funding difficulties ... Of course Rain Oncology may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying. best mobile banking app android Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ...